Alfasigma Acquires Rights to Adibelivir for HSV Encephalitis

Alfasigma S.p.A. has secured exclusive global rights from Innovative Molecules GmbH to develop and market the parenteral formulation of Adibelivir for the treatment of Herpes Simplex Virus (HSV) encephalitis. This strategic partnership involves Alfasigma investing in Innovative Molecules, a clinical-stage biotechnology firm. Adibelivir, an advanced helicase-primase inhibitor, is now entering Phase 1 clinical trials for HSV encephalitis, a rare and severe neurological condition.

HSV encephalitis presents significant challenges, with current treatments failing to notably improve patient outcomes. Adibelivir aims to offer an innovative solution, enhancing viral control and potentially improving patient survival and neurological health. The disease's low incidence, yet profound impact, highlights the urgent need for new treatments.

The agreement, which includes financial terms up to €125 million, grants Alfasigma rights to the parenteral form, while Innovative Molecules retains rights to other formulations. This partnership underscores the clinical and commercial promise of Adibelivir.